Posted in: information

Aijie Boya and Boyun biology merged and completed tens of millions of a-round financing

On April 25th, 2022, Aijie Boya biological group (abbreviated as Aijie Boya biological) announced that it had completed a round of financing of tens of millions of yuan, which was led by SANY innovation investment, a well-known investment institution in the industry, and participated in Tongchuang Weiye, Yuanhe holdings and Shangshi investment.

Aijie Boya biology is a strategic integration of Tianjin Boyun purification equipment and Material Technology Co., Ltd., a manufacturer of chromatographic fillers and specific separation and extraction materials in the pharmaceutical industry, Suzhou Aijie Boya bioelectronics Technology Co., Ltd., a manufacturer of biomedical automation instruments and equipment, and Zhejiang Boyi Biotechnology Co., Ltd., a manufacturer of industrial chromatographic automation equipment. It is a medical instrument and magnetic solid-phase material company, focusing on magnetic solid-phase extraction (MSPE) and its applications, which can be extended to any traditional solid-phase extraction applications, including food, drugs, traditional Chinese medicine and other fields.

In addition,On the 22nd of that month, Tianjin Boyun purification equipment and Materials Technology Co., Ltd., a manufacturer of chromatographic filler/specific separation and extraction materials in the pharmaceutical industry, Suzhou Aijie Boya bioelectronics Technology Co., Ltd., a manufacturer of biomedical automation instruments and equipment, and Zhejiang Boyi Biotechnology Co., Ltd., a manufacturer of industrial chromatographic automation equipment, recently completed strategic integration. This integration has formed Aijie Boya biological group (abbreviated as Aijie Boya biological group), which integrates the integrated solution of industrial chromatography separation and purification and the automatic R & D and production of clinical mass spectrometry pretreatment, and recently completed a round of financing of tens of millions of yuan. This round of financing is led by SANY innovation investment, a well-known investment institution in the industry, with the joint participation of Yuanhe holdings, Tongchuang Weiye and Shangshi investment.

The merged Aijie Boya biology has three product development and production bases located in Suzhou Industrial Park, Zhejiang Jiaxing Science and technology city and Tianjin Binhai New Area. At the same time, with Suzhou as the center, it has established supporting application support and customer service centers all over the country. Aijie Boya biology has gathered a group of high-level technical and management talents. The core team members include academicians of the Chinese Academy of Sciences, experts of the national talent plan, and a number of high-tech personnel from well-known enterprises and institutions at home and abroad. Aijie Boya biology expects to achieve a main business income of more than 80million yuan in 2022。 Through the merger, Aijie Boya biology has strongly expanded its strategic deployment in the fields of biomedicine and clinical mass spectrometry. It will gather leading technologies in three aspects:separation medium, automatic fluid control and separation equipment, and drug purification process development to provide extraction and separation products and overall solutions.At present, many original innovative and domestic alternative products of the company have been recognized and widely used by many well-known enterprises in the industry, such as the industrialized production of the third generation silica gel matrix chromatographic materials, and the full-automatic magnetic solid phase extraction technology used in the pretreatment of clinical mass spectrometry samples, so as to solve the”neck sticking” technical problem for customers. Aijie Boya biological owns and implements the dual brand strategy of”Aijie Boya” and”Boyun biological”: